# To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.

> **NCT01054261** · PHASE1 · COMPLETED · sponsor: **VIVUS LLC** · enrollment: 24 (actual)

## Conditions studied

- Renal

## Interventions

- **DRUG:** avanafil

## Key facts

- **NCT ID:** NCT01054261
- **Lead sponsor:** VIVUS LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01054261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01054261, "To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01054261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*